Ridogrel: An Antiplatelet Agent with Antihypertensive Properties

Abstract

Ridogrel is a member of the class of drugs known as thromboxane receptor antagonists/thromboxane synthase inhibitors or TRASIs. In vitro and in vivo studies have confirmed it selectively reduces thromboxane A 2 (TXA 2 ) synthesis in platelets and elsewhere, while leaving the synthesis of other eicosanoids unchanged or even increased. Theoretically, it should produce a greater overall antithrombotic effect than aspirin. Some animal and human studies support this concept. A large phase III study confirmed the safety and efficacy of ridogrel in patients following myocardial infarction. It may also be useful in other clinical situations. In spontaneously hypertensive-stroke prone rats, ridogrel reduces blood pressure, but increases plasma renin activity. The antihypertensive effect is potentiated by losartan. an angiotensin-type I receptor antagonist. Ridogrel may also have efficacy in pregnancy induced hypertension, inflammatory bowel disease, and asthma.

Prediction of Steady-State Volume of Distribution of Acidic Drugs by Quantitative Structure–Pharmacokinetics Relationships

“…Hoke et al52 found VD ss for gavestinel in the range 0.16–0.28 L/kg, which falls in the twofold error of our prediction. Wilson and Quest53 gave VD ss of 0.1–0.2 L/kg for ridogrel, which is also in the twofold error of our predicted value. Levocabastine follows two‐compartment distribution 54.…”

A review on oxime functionality: an ordinary functional group with significant impacts in supramolecular chemistry

“…Some other oxime-ether based drug molecules such as siponimod ( Oxm-15 ), 34 ridogrel ( Oxm-16 ), 35 fluvoxamine ( Oxm-17 ), 36 technetium-99m-exametazime ( Oxm-18 ), 37 oxiconazole ( Oxm-19 ), 38 olesoxime ( Oxm-20 ), 39 gemifloxacin mesylate ( Oxm-21 ), 40 etc were showed different medicinal activities (Fig. 5).…”

“…34 Ridogrel ( Oxm-16 ) is a thromboxane synthase inhibitor and thromboxane receptor antagonist (TRASI) that is used as an antiplatelet medication with antihypertensive properties. 35 Ridogrel ( Oxm-16 ) works by inhibiting thromboxane A2 (TXA 2 ) synthesis and receptor activation, which helps prevent blood clot formation and is used in the management of thrombotic disorders.…”